mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer

Science Translational Medicine - United States
doi 10.1126/scitranslmed.3005747
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Association for the Advancement of Science (AAAS)

Related search

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer

Cancer Discovery
Oncology
2018English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Approaching Resistance to Targeted Inhibition of PI3K in Breast Cancer

2011English

Effective Use of PI3K and MEK Inhibitors to Treat Mutant Kras G12D and PIK3CA H1047R Murine Lung Cancers

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2008English

FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer

Cancers
Cancer ResearchOncology
2019English

Differential Compensation Mechanisms Define Resistance to PI3K Inhibitors in PIK3CA Amplified HNSCC

Otorhinolaryngology-Head and Neck Surgery
2016English

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Cancer Discovery
Oncology
2016English

Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy